150
Participants
Start Date
March 5, 2018
Primary Completion Date
September 25, 2020
Study Completion Date
September 25, 2020
Tezepelumab
Tezepelumab subcutaneous injection
Placebo
Placebo subcutaneous injection
Research Site, San Fernando
Research Site, Lutsk
Research Site, Mendoza
Research Site, Berlin
Research Site, The Bronx
Research Site, Berlin
Research Site, Berlin
Research Site, Homestead
Research Site, Bursa
Research Site, Altoona
Research Site, Philadelphia
Research Site, Newark
Research Site, Vinnytsia
Research Site, Hamburg
Research Site, Lübeck
Research Site, Durham
Research Site, Greenville
Research Site, North Charleston
Research Site, Anderson
Research Site, Hanover
Research Site, Istanbul
Research Site, Kissimmee
Research Site, Kissimmee
Research Site, Daegu
Research Site, Toledo
Research Site, Cleveland
Research Site, Manisa
Research Site, Cincinnati
Research Site, Ann Arbor
Research Site, Dnipro
Research Site, Mainz Am Rhein
Research Site, Koblenz
Research Site, St Louis
Research Site, Aschaffenburg
Research Site, Kherson
Research Site, Oklahoma City
Research Site, McKinney
Research Site, San Antonio
Research Site, München
Research Site, Bakersfield
Research Site, Bamberg
Research Site, Fall River
Research Site, Buenos Aires
Research Site, Ciudad de Buenos Aire
Research Site, Córdoba
Research Site, Quilmes
Research Site, San Miguel de Tucumán
Research Site, Hanover
Research Site, Krakow
Research Site, Lodz
Research Site, Wroclaw
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Adana
Research Site, Ankara
Research Site, Ankara
Lead Sponsor
Collaborators (1)
Amgen
INDUSTRY
AstraZeneca
INDUSTRY